tetano
Editor, Senior Moderator
Microbiol Spectr
. 2021 Nov 10;e0099621.
doi: 10.1128/Spectrum.00996-21. Online ahead of print.
Evaluation of Sample Pooling for SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples with the Idylla SARS-CoV-2 Test
Paul Hofman[SUP] 1 2 3 [/SUP], Maryline Allegra[SUP] 2 [/SUP], Myriam Salah[SUP] 2 [/SUP], Jonathan Benzaquen[SUP] 4 [/SUP], Virginie Tanga[SUP] 1 2 [/SUP], Olivier Bordone[SUP] 1 2 [/SUP], Julien Fayada[SUP] 2 [/SUP], Elodie Long-Mira[SUP] 1 [/SUP], Sandra Lassalle[SUP] 1 [/SUP], Elisabeth Lanteri[SUP] 1 [/SUP], Virginie Lespinet-Fabre[SUP] 1 2 [/SUP], Patrick Brest[SUP] 3 [/SUP], Baharia Mograbi[SUP] 3 [/SUP], Charlotte Maniel[SUP] 4 [/SUP], Jacques Boutros[SUP] 4 [/SUP], Sylvie Leroy[SUP] 4 [/SUP], Simon Heeke[SUP] 5 [/SUP], Véronique Hofman[SUP] 1 2 3 [/SUP], Charles-Hugo Marquette[SUP] 3 4 [/SUP], Marius Ilié[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Due to increased demand for testing, as well as restricted supply chain resources, testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continues to face many hurdles. Pooling several samples has been proposed as an alternative approach to address these issues. We investigated the feasibility of pooling nasopharyngeal swab (NPS) or saliva samples for SARS-CoV-2 testing with a commercial assay (Idylla SARS-CoV-2 test; Biocartis). We evaluated the 10-pool and 20-pool approaches for 149 subjects, with 30 positive samples and 119 negative samples. The 10-pool approach had sensitivity of 78.95% (95% confidence interval [CI], 54.43% to 93.95%) and specificity of 100% (95% CI, 71.51% to 100%), whereas the 20-pool approach had sensitivity of 55.56% (95% CI, 21.20% to 86.30%) and specificity of 100% (95% CI, 25% to 100%). No significant difference was observed between the results obtained with pooled NPS and saliva samples. Given the rapidity, full automation, and practical advantages of the Idylla SARS-CoV-2 assay, pooling of 10 samples has the potential to significantly increase testing capacity for both NPS and saliva samples, with good sensitivity. IMPORTANCE To control outbreaks of coronavirus disease 2019 (COVID-19) and to avoid reagent shortages, testing strategies must be adapted and maintained for the foreseeable future. We analyzed the feasibility of pooling NPS and saliva samples for SARS-CoV-2 testing with the Idylla SARS-CoV-2 test, and we found that sensitivity was dependent on the pool size. The SARS-CoV-2 testing capacity with both NPS and saliva samples could be significantly expanded by pooling 10 samples; however, pooling 20 samples resulted in lower sensitivity.
Keywords: COVID-19; Idylla test; SARS-CoV-2; pooling.
. 2021 Nov 10;e0099621.
doi: 10.1128/Spectrum.00996-21. Online ahead of print.
Evaluation of Sample Pooling for SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples with the Idylla SARS-CoV-2 Test
Paul Hofman[SUP] 1 2 3 [/SUP], Maryline Allegra[SUP] 2 [/SUP], Myriam Salah[SUP] 2 [/SUP], Jonathan Benzaquen[SUP] 4 [/SUP], Virginie Tanga[SUP] 1 2 [/SUP], Olivier Bordone[SUP] 1 2 [/SUP], Julien Fayada[SUP] 2 [/SUP], Elodie Long-Mira[SUP] 1 [/SUP], Sandra Lassalle[SUP] 1 [/SUP], Elisabeth Lanteri[SUP] 1 [/SUP], Virginie Lespinet-Fabre[SUP] 1 2 [/SUP], Patrick Brest[SUP] 3 [/SUP], Baharia Mograbi[SUP] 3 [/SUP], Charlotte Maniel[SUP] 4 [/SUP], Jacques Boutros[SUP] 4 [/SUP], Sylvie Leroy[SUP] 4 [/SUP], Simon Heeke[SUP] 5 [/SUP], Véronique Hofman[SUP] 1 2 3 [/SUP], Charles-Hugo Marquette[SUP] 3 4 [/SUP], Marius Ilié[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 34756076
- DOI: 10.1128/Spectrum.00996-21
Abstract
Due to increased demand for testing, as well as restricted supply chain resources, testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continues to face many hurdles. Pooling several samples has been proposed as an alternative approach to address these issues. We investigated the feasibility of pooling nasopharyngeal swab (NPS) or saliva samples for SARS-CoV-2 testing with a commercial assay (Idylla SARS-CoV-2 test; Biocartis). We evaluated the 10-pool and 20-pool approaches for 149 subjects, with 30 positive samples and 119 negative samples. The 10-pool approach had sensitivity of 78.95% (95% confidence interval [CI], 54.43% to 93.95%) and specificity of 100% (95% CI, 71.51% to 100%), whereas the 20-pool approach had sensitivity of 55.56% (95% CI, 21.20% to 86.30%) and specificity of 100% (95% CI, 25% to 100%). No significant difference was observed between the results obtained with pooled NPS and saliva samples. Given the rapidity, full automation, and practical advantages of the Idylla SARS-CoV-2 assay, pooling of 10 samples has the potential to significantly increase testing capacity for both NPS and saliva samples, with good sensitivity. IMPORTANCE To control outbreaks of coronavirus disease 2019 (COVID-19) and to avoid reagent shortages, testing strategies must be adapted and maintained for the foreseeable future. We analyzed the feasibility of pooling NPS and saliva samples for SARS-CoV-2 testing with the Idylla SARS-CoV-2 test, and we found that sensitivity was dependent on the pool size. The SARS-CoV-2 testing capacity with both NPS and saliva samples could be significantly expanded by pooling 10 samples; however, pooling 20 samples resulted in lower sensitivity.
Keywords: COVID-19; Idylla test; SARS-CoV-2; pooling.